This study provides several layers of evidence that STK25 is an interesting new mediator in the interconnected metabolic network controlling skeletal muscle insulin sensitivity, and that the development of STK25 antagonists for therapeutic applications in type 2 diabetes and related metabolic disease is warranted. This evidence concerns the gene INS and Other metabolic disease.